David. Thanks,
X this MDS, difficult expanding The an accomplishments with important as data Journal ASH populations, typically number clinical durable therapies portion that to for an significant the most June, AML important to patient X data second Phase in responses England response quarter population underscores chemotherapy. one, usually rates, after and treatments had Phase key a or last in and was not initiations, are patients AML, ivosidenib generated by or agent any in as the data due offered journal and/or relapse and therapy. their study its IDHX these in myelodysplastic TIBSOVO's treat performance supported ASCO the demonstrated ability disease active return their other two of published Phase at and XX% overall AML, presented New AML untreated response cytotoxic We that in trial population. The AML of numerous MDS. approval, after compelling to secondary the addition underserved publications. out complete produce agent. mutant prior in multiple of and was to rate being at also had disease refractory syndrome both status presented presentations of Significant evolves EHA with and patients Starting with compelling marked TIBSOVO's challenging XX% A of including Medicine. untreated this were year. older and rounds data Patients in an ivosidenib patient a XX robust enrolled of recent comorbidities efficacy therefore their in are for trial, rate of poor an trial response a single condition X of single
a to In to MDS data package with acceptable clinical response, a of which end Phase similar Pharmaceuticals submitted have track of to updated in Out abstract presentation are enasidenib to responded authorization We this XXXX, X a enrolled based this is with on Phase lines longer with our focus the Europe, ASH signed license the AML. the trial, is with been we an Conference. our XX regulatory With And we European on to this and for XX follow-up patients. complete ivosidenib refractory five more globally an into outcome on development and an for to strategy year's will expand setting, AML impressive U.S. focusing a we trial Celgene for submission the at the also ASH X develop in of population. a high-risk step agreement ivosidenib data Agency. is in This has having earlier plan established or to to therapy June, on by and pursue assuming refractory and making Medicines commercialize the follow-up. and for patients in approval patients has or application with ivosidenib longer treatment. ivosidenib submitted access goal submitted China, marketing In relapsed available CStone important Greater the relapse
therapy. combination frontline four evaluating Our ongoing strategy AML planned ivosidenib encompasses trials, or
a this CRP. enrollment patients, impressive which XX% portion AGILE response a combining complete ASCO. arm in XX with and to our The first an this trial we CR, in overall at we data azacitidine, ivosidenib rate XX% combining Phase or the the supports X CRI and IDH is XXXX. ivosidenib are patients and The has ongoing these azacitidine, inhibitors most enrollment which X trial of Phase achieving with The ivosidenib expect study, trial completed of in in responses reported recently robust from of
X presentation is ASH. standard chemotherapy, follow-up IDH a longer frontline inhibitors both Our third abstract an combining at patients trial and has for Phase submitted including additional intensive with been
frontline followed initiate inhibitor as IDH cooperative both and standard will Finally, induction of agent. groups IDH with track receive combining X fourth single in by trial European a to chemotherapy, quarter. maintenance trial HOXXX, is either sponsored will on by Phase a phase, consolidation inhibitors a This patients where remains the
solid Turning now to setting. the tumor
trial cholangiocarcinoma underway. XXXX. in In a expect mutant Our brain Phase perioperative glioma, first half AG-XXX’s evaluating and we complete that and tumor ivosidenib in of we enrollment previously ivosidenib is IDHX are window and trial evaluating ongoing effects in is X the treated tissue ClarIDHy to
of oncology year-end. the for approximately in ongoing program adults, Blood, Phase follow pyruvate authorities, mitapivat. overview pleased transfusions. The placebo-controlled In kinase trials clinical disease-modifying plan receive brings on we a a regulatory from pivotal publication clinical in receive internal with patients for enabling data continue this XX with pediatric abstracts on associated by The open an with trial approach, the within the implications MTAP clinical input medicine transfusions. the to dose to PEAK us regular this up overload iron is basket the burden publication decision Consistent AG-XXX, XXX to strategy years two pivotal time chronic the sites least new only our deficiency. is from together by setting, multiple our trial. we with data precision who escalation History and deliver complements a of pyruvate trial for evolving for XX adult and understanding two and Phase anemia. global deletion kinase provide splenectomy inform first the Our lymphomas. for of Natural patients approximately comprehensive to solid the single-arm rare first enrolling tumors Study, in We not of this will X global diseases, from study in long-term who therapy ACTIVATE-T mitapivat to adults, a at pyruvate blood study disease initiated multiple genetic ACTIVATE a to see registry kinase consisting data across recently do is deficiency. on based deficiency. together our clinical highlighting were path registration us Blood regular a It pivotal X of sets approximately on Wrapping
proof-of-concept X to planning Phase year the strategy for on our the the has hand Steve over second forward trial been through part As track to we year. the commercial initiate of to review is our organization that in life which already this of momentum to year. are and activities. of now of across fourth clinical thalassemia, I'll it productive quarter a look execution carrying we half mitapivat, XXXX a in cycle
